Sixfold Bioscience

sixfold.bio →

-85%

est. 2Y upside i

HealthcareSeed

Delivering RNA therapies.

Rank

#3188

Sector

Biotechnology

Est. Liquidity

~7Y

Data Quality

Data: Low

Sixfold Bioscience is a preclinical-stage biotech with a promising RNA delivery platform (Mergo®) in a large and growing market.

Last updated: March 10, 2026

Bull (15%)+400%

Sixfold Bioscience achieves a significant breakthrough in preclinical trials, demonstrating superior efficacy and safety of its Mergo® platform for a non-hepatic indication. This leads to a successful Investigational New Drug (IND) filing and a major commercial partnership with a large pharmaceutical company, validating the technology and attracting a substantial Series B funding round at a $375M valuation (5x current estimated valuation).

Base (30%)+20%

Sixfold Bioscience continues to make steady preclinical progress with its Mergo® platform, generating promising but not groundbreaking data. The company secures additional non-dilutive grants and a modest Series A/B funding round, allowing for continued R&D. Valuation sees a slight appreciation to $90M (1.2x current estimated valuation) as they advance towards early clinical development.

Bear (55%)-80%

Preclinical data for the Mergo® platform fails to demonstrate sufficient differentiation or efficacy compared to existing or emerging RNA delivery technologies from well-funded incumbents. This, coupled with the high capital intensity of biotech R&D, leads to difficulties in securing further significant funding, resulting in a down round or limited exit at a valuation of $15M (-80% of current estimated valuation), severely impacting common stock value.

Est. time to liquidity~7.0 years

Preference Stack Risk

moderate

Investors hold $10.5M in liquidation preferences. In an exit at or below $10.5M, common shareholders would receive nothing. At the estimated current valuation of $75M, common shareholders would receive $64.5M after preferences.

Dilution Risk

high

As a preclinical biotech, Sixfold Bioscience will require multiple, large funding rounds to advance through clinical trials and potential commercialization, leading to significant future dilution for existing equity holders.

Secondary Liquidity

none

As an early-stage, privately held company, there is currently no active secondary market or tender offers for Sixfold Bioscience equity.

Other — 1 role

View all 1 open roles at Sixfold Bioscience →

Last updated: March 10, 2026

Questions to Ask at the Interview

Strategic questions based on Sixfold Bioscience's data — designed to show you've done your homework.

  • 1

    “Given the strong competitive landscape with established players like Moderna and Arcturus Therapeutics, how does Sixfold Bioscience plan to differentiate its Mergo® platform to secure market share and strategic partnerships, particularly for non-hepatic delivery?”

  • 2

    “As a preclinical company, what are the critical milestones and estimated timelines for advancing the Mergo® platform into clinical trials, and what is the projected capital required for these stages?”

  • 3

    “Considering the long development cycles and high capital intensity in biotech, what is the company's strategy for future fundraising, and how does it plan to manage potential dilution for early employees holding common stock or options?”

Community

Valuation Sentiment

Our model estimates -85% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.